M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine-Reference-Cited by-同舟云学术

M7824, a novel bifunctional anti-PD-L1/TGFβ Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine

Published:2018-02-14 Issue:5 Volume:7 Page:e1426519
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Knudson Karin M.¹,Hicks Kristin C.¹,Luo Xiaoling²,Chen Jin-Qiu²,Schlom Jeffrey¹,Gameiro Sofia R.¹

Affiliation:

1. Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

2. Collaborative Protein Technology Resource (CPTR), Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

Funder

Cooperative Research and Development Agreement between the National Cancer Institute and EMD Serono, Inc.

Intramural Research Program, CCR, NCI, NIH

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2018.1426519

Reference64 articles.

1. Immune Checkpoint Blockade in Cancer Therapy

2. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations